idea
behind
revers
vaccinolog
screen
entir
pathogen
genom
find
gene
encod
protein
attribut
good
vaccin
target
exampl
bacteri
surfac
associ
protein
protein
undergo
normal
laboratori
evalu
immunogen
neisseria
meningitidi
serogroup
b
menb
revers
vaccinolog
project
provid
proof
concept
type
approach
project
identifi
novel
vaccin
candid
month
discov
year
convent
vaccinolog
analysi
genom
sequenc
virul
menb
strain
found
predict
open
read
frame
orf
screen
use
bioinformat
tool
identifi
orf
predict
encod
surfaceexpos
secret
protein
might
access
immun
system
antigen
screen
continu
basi
sever
criteria
abil
antigen
express
escherichia
coli
recombin
protein
candid
confirm
elisa
flow
cytometri
antigen
expos
cell
surfac
candid
abil
induc
antibodi
elicit
kill
measur
serum
bactericid
assay
andor
passiv
protect
infant
rat
assay
candid
screen
panel
divers
meningococc
isol
determin
whether
antigen
conserv
approach
result
develop
multicompon
recombin
menb
vaccin
enter
phase
iii
clinic
trial
multipl
genom
sequenc
becom
avail
singl
speci
concept
pangenom
revers
vaccinolog
emerg
power
tool
identifi
vaccin
candid
antigen
divers
speci
pangenom
aim
identifi
full
complement
gene
speci
base
superset
gene
sever
strain
speci
analysi
genom
sequenc
eight
streptococcu
agalactia
also
known
group
b
streptococcu
strain
reveal
substanti
genet
heterogen
extend
gene
repertoir
speci
screen
found
total
gene
predict
encod
surfaceexpos
secret
protein
agalactia
pangenom
core
genom
conserv
dispens
genom
present
two
strain
henc
consid
dispens
surviv
base
screen
pool
candid
includ
abil
recombin
protein
provid
protect
use
immun
anim
combin
four
one
core
select
shown
confer
protect
panel
agalactia
strain
wherea
genom
sequenc
project
typic
focus
pathogen
organ
comparison
genom
pathogen
nonpathogen
strain
allow
vaccin
drug
target
identifi
basi
protein
specif
involv
pathogenesi
compar
studi
commens
pathogen
e
coli
genom
identifi
gene
uniqu
certain
pathogen
strain
larg
absent
commens
strain
filter
decreas
pool
target
screen
potenti
limit
detriment
effect
therapeut
composit
commens
flora
new
sequenc
technolog
also
open
opportun
monitor
pathogen
vaccin
escap
screen
evid
immun
select
genom
pathogen
popul
vaccin
select
deepsequenc
bacteri
viral
popul
possibl
identifi
antigen
immun
select
monitor
cluster
singl
nucleotid
polymorph
snp
mutat
affect
protein
sequenc
approach
alreadi
use
search
evid
antigen
variationselect
popul
salmonella
enterica
serovar
typhi
variat
extrem
limit
similar
sequenc
strategi
could
appli
popul
bacteria
taken
vaccin
trial
particular
geograph
region
pathogen
gene
upregul
infect
andor
essenti
microorgan
surviv
pathogenesi
identifi
use
transcriptom
ie
analysi
near
complet
set
rna
transcript
express
pathogen
specifi
condit
comprehens
dnabas
microarray
chip
probe
cdna
gener
rna
revers
transcript
ultrahighthroughput
sequenc
technolog
allow
rapid
sequenc
direct
quantif
cdna
enabl
transcriptom
pathogen
character
particular
type
gene
product
identifi
exampl
gene
involv
hyperinfecti
state
vibrio
cholera
appear
passag
human
gastrointestin
tract
identifi
comparison
transcriptom
bacteria
isol
directli
stool
sampl
cholera
patient
v
cholera
grown
vitro
similarli
analysi
transcript
profil
tuberculosi
earli
infect
immunecompet
balbc
sever
combin
immunodefici
scid
mice
reveal
set
gene
activ
exclus
respons
host
immun
system
function
genotyp
transcriptom
proteom
appli
mani
pathogen
identifi
gene
essenti
surviv
virul
may
valid
vaccin
candid
dna
microarray
use
screen
comprehens
librari
pathogen
mutant
compar
bacteri
isol
passag
anim
model
exposur
compound
librari
identifi
attenu
clone
exampl
method
use
identifi
novel
menb
gene
requir
pathogen
caus
septicemia
infant
rat
gene
essenti
h
pylori
gastric
colon
gerbil
gene
contribut
tuberculosi
persist
host
analysi
pathogen
proteom
near
complet
set
protein
express
specifi
condit
reveal
potenti
vaccin
drug
candid
add
signific
valu
silico
approach
highthroughput
proteom
analys
perform
use
mass
spectrometri
ms
chromatograph
techniqu
protein
microarray
novel
proteomebas
approach
appli
identifi
surfac
protein
ga
make
use
proteolyt
enzym
shave
bacteri
surfac
releas
expos
protein
partial
expos
peptid
seventeen
surfac
protein
virul
ga
strain
identifi
way
use
ms
genom
sequenc
analysi
locat
pathogen
surfac
confirm
flow
cytometri
one
provid
protect
immun
mous
model
diseas
proteom
pathogen
also
screen
identifi
immunom
near
complet
set
pathogen
protein
epitop
interact
host
immun
system
use
vitro
silico
techniqu
vitro
identif
screen
immunom
base
idea
antibodi
present
serum
host
expos
pathogen
repres
molecular
imprint
pathogen
immunogen
protein
use
identifi
vaccin
candid
sever
techniqu
develop
allow
highthroughput
display
pathogen
protein
subsequ
screen
protein
interact
antibodi
sera
immunogen
surfac
protein
sever
organ
identifi
includ
aureu
use
membran
blot
ms
agalactia
pyogen
streptococcu
pneumonia
use
phage
e
colibas
comprehens
genom
peptid
express
librari
francisella
tularensi
caus
agent
tularemia
rabbit
fever
v
cholera
use
protein
microarray
chip
protein
microarray
protein
pathogen
spot
onto
microarray
chip
also
use
character
interact
well
acid
interact
abil
predict
silico
pathogen
epitop
recogn
b
cell
cell
greatli
improv
recent
year
largescal
screen
pathogen
includ
hiv
bacillu
anthraci
tuberculosi
f
tularensi
yersinia
pesti
caus
agent
bubon
plagu
flavivirus
influenza
b
cell
cell
epitop
current
underway
although
epitop
predict
foolproof
serv
guid
biolog
evalu
cell
epitop
present
mhchla
protein
surfac
antigenpres
cell
vari
consider
host
complic
task
function
epitop
predict
addit
b
cell
epitop
linear
conform
ultim
aim
research
field
studi
would
engin
singl
peptid
repres
defin
epitop
combin
protein
organ
enabl
genet
variabl
pathogen
host
overcom
structur
studi
threedimension
structur
protein
produc
increasingli
appli
vaccin
drug
develop
result
explos
genom
proteom
data
continu
improv
field
protein
express
purif
structur
determin
structurebas
design
antivir
therapeut
led
develop
drug
direct
activ
site
proteas
influenza
neuraminidas
highresolut
protein
structur
avail
public
databas
see
http
wwwwwpdborgstatshtml
sever
initi
establish
pursu
highthroughput
character
protein
structur
genomewid
scale
focus
determin
understand
structur
basi
immunedomin
immunerecess
antigen
well
protein
activ
site
potenti
drugbind
site
exampl
structur
character
hiv
envelop
protein
reveal
mechan
use
viru
evad
host
antibodi
respons
mani
involv
hypervari
immunodomin
epitop
base
inform
immun
refocus
eg
retarget
glycosyl
delet
andor
substitut
amino
acid
use
dampen
respons
variabl
immunodomin
epitop
envelop
glycoprotein
enabl
host
respond
previous
subdomin
epitop
highthroughput
modif
protein
screen
immunogen
interact
antimicrobi
predict
becom
common
techniqu
evolv
design
new
vaccin
one
import
consider
risk
vaccin
might
gener
self
immun
reaction
host
epitop
immun
respons
pathogen
antigen
crossreact
host
antigen
homolog
exist
primari
amino
acid
sequenc
structur
potenti
lead
damag
host
tissu
drug
aim
pathogen
target
could
also
theoret
target
similar
host
molecul
avail
human
genom
sequenc
combin
method
predict
b
cell
cell
epitop
facilit
screen
presenc
homolog
candid
microbi
vaccin
antigen
protein
human
enabl
issu
autoimmun
crossreact
tackl
vaccin
drug
target
identifi
use
method
base
pathogen
genom
screen
homolog
similar
human
protein
silico
use
program
blast
basic
local
align
search
tool
http
blastncbinlmnihgovblastcgi
queri
human
genom
databas
interestingli
analysi
viral
genom
reveal
around
viral
pentapeptid
could
compon
epitop
ident
human
peptid
littl
homolog
howev
valid
immunogen
diseaseassoci
peptidesepitop
host
peptid
suggest
screen
approach
includ
predict
immunogen
could
improv
pool
target
candid
import
keep
mind
fulli
understand
selftoler
broken
current
perfect
way
predict
potenti
autoimmun
trigger
could
associ
vaccin
mani
link
made
autoimmun
diseas
vaccin
confirm
small
number
case
review
exampl
treatmentresist
lyme
arthriti
associ
certain
patient
immun
reactiv
outer
surfac
protein
ospa
caus
agent
lyme
diseas
borrelia
burgdorferi
ospa
epitop
homolog
human
lymphocyt
functionassoci
antigen
hlfa
result
ospabas
lyme
diseas
vaccin
lymerix
taken
market
recombin
ospa
lack
potenti
autoreact
cell
epitop
propos
replac
vaccin
rather
target
drug
pathogen
enzym
altern
approach
focus
target
hostcel
protein
exploit
pathogen
replic
surviv
use
techniqu
includ
microarraybas
analysi
virusinduc
host
gene
express
reveal
sever
possibl
target
cholesterollow
drug
statin
exampl
antihiv
effect
believ
mediat
prevent
activ
host
protein
rho
activ
hiv
envelop
protein
requir
viru
entri
cell
furthermor
studi
improv
understand
host
immun
respons
protect
pathogen
ie
innat
antibodi
respons
aid
select
appropri
vaccin
adjuv
exampl
induct
interferon
signal
earli
infect
may
critic
confer
protect
sarscov
determin
function
genom
studi
earli
host
respons
sarscov
infect
lung
macaqu
mani
gene
human
immun
system
highli
polymorph
enabl
popul
whole
gener
suffici
immunolog
divers
combat
eid
variat
also
impact
outcom
vaccin
treatment
intern
hapmap
project
identifi
million
snp
individu
genom
project
aim
identifi
even
genet
variant
field
vaccinom
also
call
immunogenet
investig
heterogen
host
genet
marker
result
variat
vaccineinduc
immun
respons
aim
predict
minim
vaccin
failur
advers
event
exampl
polymorph
hla
immunoregulatori
cytokin
receptor
gene
associ
variabl
outcom
vaccin
mump
similarli
pharmacogenet
investig
genet
differ
way
individu
metabol
therapeut
found
human
variabl
speed
metabol
common
firstlin
tuberculosi
drug
isoniazid
associ
genet
variant
includ
snp
gene
encod
arylamin
nacetyltransferas
abil
predict
individu
respons
vaccin
drug
may
eventu
allow
physician
determin
whether
patient
genet
suscept
diseas
possibl
advers
effect
vaccin
drug
appropri
schedul
dose
use
predict
genom
greatli
aid
control
eid
increas
effici
vaccin
therapeut
target
identifi
use
genomebas
approach
describ
furthermor
anticip
continu
refin
develop
novel
genomebas
approach
sequenc
becom
faster
afford
sever
challeng
remain
howev
identif
target
process
need
bring
new
vaccin
drug
market
understand
molecular
natur
epitop
mechan
action
adjuv
cell
mucos
immun
key
prioriti
tackl
come
year
issu
address
improv
structur
studi
antigen
epitop
compil
databas
contain
inform
structur
immunogen
silico
b
cell
cell
epitop
predict
genomebas
develop
effect
vaccin
therapeut
still
larg
depend
avail
valid
model
measur
efficaci
protect
diseas
howev
increas
understand
microbi
pathogenesi
emerg
genom
greatli
aid
respect
likewis
continu
develop
anim
model
knockout
allelespecif
mutat
key
compon
immun
respons
greatli
increas
understand
type
immun
respons
need
control
diseas
way
immun
system
program
protect
host
diseas
unfortun
stepwis
seri
prelicensur
clinic
trial
phase
ii
iii
requir
document
safeti
immunogen
efficaci
vaccin
still
highli
timeconsum
costli
hope
increasingli
smart
identif
design
target
fresh
impetu
given
field
vaccin
drug
develop
arriv
genom
enabl
increas
success
vaccin
drug
make
clinic
develop
